Skip to main content

Table 1 A—Clinical characteristics of the 7 stage IIIc melanoma patients with pelvic locoregional metastases. B—Liquid biopsy metastatic melanoma CTC chemosensitivity assays

From: Circulating tumour cell liquid biopsy in selecting therapy for recurrent cutaneous melanoma with locoregional pelvic metastases: a pilot study

Part AAge (years)Burden≥ 1 mitosis/mm2ChromotypeBRAFV600E statusPercentage of MGMT promoter methylationPrevious therapiesConcomitant diseases
-therapies
RECIST 1.1 responseProgression-free survival from 1st melphalan HPP
-site of progression
Therapies at progressionCensor
-Overall survival from 1st melphalan HPP
   
Pt 150HighNotBlackWild-type10Surgery
Interferon alpha
Hepatitis C
-Sofosbuvir and daclatasvir
SD3 months
-locoregional
2nd melphalan HPPDead
-17 months
   
Pt 255LowYesBlackWild-type14.2Surgery
Dacarbazine systemic chemotherapy
Inflammatory bowel disease
-corticosteroids
SD2 months
-locoregional
2nd melphalan HPP;
Platinum ECT
Dead
-47 months
   
Pt 360HighYesRedWild-type20.2SurgeryHepatitis C
-Sofosbuvir and daclatasvir
PR3 months
-locoregional and distant
Dacarbazine systemic chemotherapyDead
-19 months
   
Pt 461HighYesBlackWild-type12.2SurgeryHepatitis C
-Sofosbuvir and daclatasvir
SD3 months
-locoregional and distant
Gemcitabine, paclitaxel systemic chemotherapyDead
-7 months
   
Pt 585LowNotBlackWild-type21.2Surgery
Interferon alpha
Inflammatory bowel disease
-corticosteroids
SD3 months
-locoregional
2nd melphalan HPP; surgeryDead
-21 months
   
Pt 638LowNotRedWild-type16.2Surgery
Radiation therapy
Dacarbazine systemic chemotherapy
Inflammatory bowel disease
-corticosteroids
Lymphoma NH B-CLL
-corticosteroids
SD4 months
-locoregional
2nd melphalan HPP; surgeryDead
-21 months
   
Pt 775HighNotBlackWild-type28.5Surgery
-Bleomycin ECT
Hepatitis C
-Sofosbuvir and daclatasvir
SD4 months
-locoregional and distant
Dacarbazine systemic chemotherapyDead
-15 months
   
Part BIV-CTCs5-FU (%)Gem (%)Dacarb (%)Epi (%)Alk (%)Eto (%)Carbo (%)Cis (%)Ox (%)Paclit (%)Doce (%)Vino (%)Topo (%)Iri (%)
Pt 19.6 ml, SD ± 0.3 cellsS = 30S = 90S = 80S = 30S = 60S = 40S = 45S = 30S = 30S = 85S = 58S = 20S = 20S = 30
Pt 216.2/ml, SD ± 0.3 cellsS = 30S = 85S = 80S = 25S = 50S = 50S = 75S = 90S = 40S = 50S = 50S = 50S = 30S = 30
Pt 36.4/ml, SD ± 0.3 cellsS = 20S = 50S = 70S = 30S = 65S = 25S = 30S = 50S = 30S = 30S = 40S = 30S = 25S = 20
Pt 48.4/ml, SD ± 0.3 cellsS = 25S = 85S = 72S = 25S = 54S = 24S = 20S = 30S = 30S = 90S = 50S = 30S = 30S = 30
Pt 59.8/ml, SD ± 0.3 cellsS = 35S = 65S = 30S = 31S = 72S = 23S = 30S = 30S = 30S = 95S = 60S = 30S = 30S = 30
Pt 69.2/ml, SD ± 0.3 cellsS = 25S = 30S = 95S = 25S = 84S = 90S = 42S = 35S = 35S = 20S = 20S = 25S = 20S = 20
Pt 79.8/ml, SD ± 0.3 cellsS = 50S = 50S = 75S = 20S = 50S = 50S = 50S = 40S = 50S = 85S = 30S = 30S = 20S = 20
  1. Low burden (< 10 nodules; or no lesion > 3 cm); High burden (≥ 10 nodules; or one lesion > 3 cm); ECT electrochemotherapy, NH B-CLL non-Hodgkin B lymphocytes, PR partial response, SD stable disease, Pt patient, IV-CTCs isolated viable circulating tumor cells, 5-FU 5 fluorouracil, Gem = gemcitabine, Epi epirubicin, Alk melphalan, Eto etoposide, Carbo carboplatin, Cis cisplatin, Ox oxaliplatin, Paclit paclitaxel, Doce docetaxel, Vino vinorelbine, Topo topotecan, Iri irinotecan, S sensitivity
\